Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Ulcerative Colitis

Ulcerative Colitis

Part of Inflammatory Bowel Disease

30 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Ulcerative Colitis

188 trials tracked for Ulcerative Colitis: 76 in phase 3 or 4 and 46 with published results. The most-cited published study has 721 citations.

188Trials tracked
76Phase 3 & 4
0Recruiting
46With published results
Phase distribution
Phase 4 13 Phase 3 63 Phase 2 64 Phase 1 10 Other / NA 38
  1. Phase 3 An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis Completed · 721 cited
  2. Phase 3 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis Completed · 314 cited
  3. Phase 3 Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis Completed · 223 cited
  4. Phase 3 An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease Completed · 190 cited
  5. Phase 4 Predicting Response to Standardized Pediatric Colitis Therapy Completed · 164 cited
  6. Phase 3 Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1) Completed · 131 cited
Show 44 more trials
  1. Phase 3 Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis Completed · 117 cited
  2. Phase 3 A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis Completed · 116 cited
  3. Phase 3 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis Completed · 116 cited
  4. Phase 3 A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis Completed · 116 cited
  5. Phase 3 Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis Completed · 99 cited
  6. Phase 3 A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors Completed · 93 cited
  7. Phase 3 A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors Completed · 92 cited
  8. Phase 3 A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors Completed · 87 cited
  9. Phase 3 A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors Completed · 87 cited
  10. Phase 3 A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors Completed · 87 cited
  11. Phase 3 A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis. Completed · 77 cited
  12. Phase 3 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis Completed · 75 cited
  13. Phase 3 Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) Completed · 74 cited
  14. Phase 3 Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD) Completed · 61 cited
  15. Phase 3 CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC) Completed · 59 cited
  16. Phase 3 A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting Completed · 44 cited
  17. Phase 3 Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan Completed · 41 cited
  18. Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Completed · 38 cited
  19. Phase 4 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) Completed · 37 cited
  20. Phase 3 Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis Completed · 33 cited
  21. Phase 4 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) Completed · 32 cited
  22. Phase 3 The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients Completed · 26 cited
  23. Phase 4 Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis Completed · 25 cited
  24. Phase 4 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed · 24 cited
  25. Phase 4 Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Completed · 23 cited
  26. Phase 3 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) Completed · 23 cited
  27. Phase 3 Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis Completed · 22 cited
  28. Phase 3 An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis Completed · 22 cited
  29. Phase 3 An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis Completed · 17 cited
  30. Phase 4 Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). Completed · 15 cited
  31. Phase 3 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease Completed · 12 cited
  32. Phase 4 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Completed · 11 cited
  33. Phase 3 Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission Completed · 7 cited
  34. Phase 3 Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis Completed · 6 cited
  35. Phase 3 Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis Completed · 5 cited
  36. Phase 3 Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Completed · 4 cited
  37. Phase 3 Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis Completed · 4 cited
  38. Phase 3 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis Completed · 3 cited
  39. Phase 4 Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Completed · 2 cited
  40. Phase 3 BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis Completed
  41. Phase 4 A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease Completed
  42. Phase 4 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis Completed
  43. Phase 4 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed
  44. Phase 4 Dose Escalation and Remission (DEAR) Completed

Showing the 50 most-cited and recently-updated of 188 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
Oncology Meta-analysis
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models Green tea compound shows potential for several digestive diseases
This meta-analysis of 63 preclinical studies involving 738 animals indicates that Epigallocatechin-3-gallate (EGCG) has a positive therapeut…
A review of animal studies suggests a green tea compound could help treat various cancers and digestive conditions.
Frontiers Jun 11, 2026
Mucus-barrier regulatory programs in Crohn's disease and ulcerative colitis involve ER stress and microbial sensing
Allergy & Immunology Meta-analysis
Mucus-barrier regulatory programs in Crohn's disease and ulcerative colitis involve ER stress and microbial sensing New findings show how mucus barriers fail in Crohn's and Ulcerative Colitis
This meta-analysis of transcriptomic datasets and an Agr2-/- mouse model identifies consensus mucus-barrier regulatory programs in active IB…
Researchers found that specific genes control the protective mucus layer in the gut. These same pathways are disrupted in people with IBD.
Frontiers Jun 9, 2026
IBD-related neuroimaging shows brain alterations in emotional networks with distinguishable phenotypes for Crohn's and ulcerative colitis
Neurology Sys. Review
IBD-related neuroimaging shows brain alterations in emotional networks with distinguishable phenotypes for Crohn's and ulcerative colitis Brain scans show different emotional patterns in Crohn's and ulcerative colitis
This bibliometric analysis and systematic scoping review examines 175 articles on IBD-related neuroimaging literature from Web of Science an…
A review of 175 articles found that brain activity in Crohn's and ulcerative colitis affects emotion centers differently. This suggests dist…
Frontiers Jun 4, 2026
Mediterranean diet shows no significant advantage over control diets for inducing remission in inflammatory bowel disease patients
Nutrition & Obesity Medicine Meta-analysis
Mediterranean diet shows no significant advantage over control diets for inducing remission in inflammatory bowel disease patients Mediterranean diet helps some patients with inflammatory bowel disease reach remission better than control diets
This systematic review and meta-analysis evaluated the Mediterranean diet versus control diets in patients with inflammatory bowel disease. …
A review of studies found that a Mediterranean diet helped about 62% of patients reach remission. This approach worked well for both Crohn's…
Jun 1, 2026
Meta-analysis of GWAS data identifies genetic risk factors for inflammatory bowel disease in 125,992 individuals
Genetics & Precision Medicine Meta-analysis
Meta-analysis of GWAS data identifies genetic risk factors for inflammatory bowel disease in 125,992 individuals Genetic map reveals new targets for inflammatory bowel disease
This meta-analysis review synthesizes genome-wide association study data from 125,992 individuals with IBD and more than 1.2 million control…
A massive genetic study found 619 new signals linked to Crohn's and ulcerative colitis, offering fresh clues for future treatments.
medRxiv May 18, 2026
Meta-analysis associates childhood antibiotic use with increased inflammatory bowel disease risk
Infectious Disease Meta-analysis
Meta-analysis associates childhood antibiotic use with increased inflammatory bowel disease risk Early antibiotics may raise your risk of developing inflammatory bowel disease later in life
This meta-analysis of 8 studies involving 2783 cases examines the association between antibiotic use in children aged 1 to 17 years and the …
New research shows that taking antibiotics during childhood could increase the chance of developing inflammatory bowel disease later in life
May 4, 2026
Extended Risankizumab Benefits Initial Nonresponders in Ulcerative Colitis
Drug Pipeline RCT
Extended Risankizumab Benefits Initial Nonresponders in Ulcerative Colitis Over half of ulcerative colitis patients found relief with longer treatment
Over 50% of patients with ulcerative colitis who did not respond to initial risankizumab achieved clinical response with 12 more weeks of ex…
More than half of patients with ulcerative colitis who did not respond to initial treatment found clinical response with extended risankizum…
May 1, 2026
Narrative review discusses NF-kB inhibition for inflammatory bowel diseases and related conditions
Gastroenterology Sys. Review
Narrative review discusses NF-kB inhibition for inflammatory bowel diseases and related conditions Blocking NF-κB May Ease Gut Inflammation in IBD
This narrative review explores the role of NF-kB pathway inhibition in treating inflammatory conditions.
A review finds that blocking a key inflammatory pathway could help treat Crohn's, colitis, and celiac disease.
Frontiers May 1, 2026
Meta-analysis shows reduced oral microbial Shannon diversity in Crohn's disease versus controls
Gastroenterology Meta-analysis
Meta-analysis shows reduced oral microbial Shannon diversity in Crohn's disease versus controls Oral bacteria shifts could reveal Crohn's disease risk
This meta-analysis reviews data from multiple cohorts involving 1,136 IBD patients and 759 controls.
A new study links distinct mouth bacteria changes to higher gut inflammation levels in Crohn's disease patients.
medRxiv Apr 29, 2026
Enteral nutrition therapy associated with clinical remission in 60% of Chinese inflammatory bowel disease patients over 6 weeks
Nutrition & Obesity Medicine Cohort
Enteral nutrition therapy associated with clinical remission in 60% of Chinese inflammatory bowel disease patients over 6 weeks Enteral nutrition helps many IBD patients reach remission faster
This retrospective cohort study evaluated enteral nutrition therapy in 750 Chinese patients with Crohn's disease or ulcerative colitis.
Special liquid food formulas helped 60% of patients reach remission faster while improving nutrition and reducing inflammation in their bodi…
Frontiers Apr 29, 2026
Three Biomarkers Show High Diagnostic Accuracy for Ulcerative Colitis in Cohort Study
Hematology Cohort
Three Biomarkers Show High Diagnostic Accuracy for Ulcerative Colitis in Cohort Study Three biomarkers show promise for diagnosing ulcerative colitis
This cohort study evaluated ARHGEF3, S100A8, and RHOU as diagnostic biomarkers for ulcerative colitis.
A new study identifies three biomarkers that may help diagnose ulcerative colitis and distinguish it from Crohn's disease.
Frontiers Apr 24, 2026
Network meta-analysis of dietary supplements for ulcerative colitis management
Rheumatology Meta-analysis
Network meta-analysis of dietary supplements for ulcerative colitis management Some dietary supplements may help ulcerative colitis symptoms and quality of life
This network meta-analysis of 24 randomized controlled trials with 1,491 participants synthesized evidence on dietary supplements for ulcera…
A review of 24 trials found certain supplements like probiotics and flaxseed extract may ease ulcerative colitis symptoms and improve qualit…
Frontiers Apr 23, 2026

Questions about Ulcerative Colitis

How does the gut bacteria diversity in ulcerative colitis compare to healthy controls?

Ulcerative colitis patients consistently show reduced gut bacterial diversity (lower Shannon index) and altered composition compared to healthy controls, with depletion of beneficial butyrate-producing bacteria and increases in certain pro-inflammatory groups.

Full answer →
Is there a link between NF-kB pathway inhibition and treating ulcerative colitis?

Yes, inhibiting the NF-κB pathway is a key treatment strategy for ulcerative colitis, as it reduces inflammation and may prevent cancer progression.

Full answer →
Are there specific biomarkers that can accurately diagnose ulcerative colitis in a new patient?

Yes, three biomarkers (ARHGEF3, S100A8, RHOU) show high diagnostic accuracy for ulcerative colitis, and bile acid ratios are also promising noninvasive markers.

Full answer →
Can enteral nutrition therapy help achieve remission in patients with ulcerative colitis?

Enteral nutrition therapy may help achieve remission in ulcerative colitis, with studies showing clinical remission rates around 60% and benefits in acute severe cases, but evidence is stronger for Crohn's disease.

Full answer →

All Ulcerative Colitis Articles